~ COVID-19 Medical News ~
Medical News on therapies and treatments being investigated:
May 30, 2020 - Hdroxychloroquine UPDATE - Scientists Worldwide Are Questioning A Massive
Study That Raised Concerns About The COVID-19 Treatment.
May 27, 2020 - Hdroxychloroquine UPDATE - EU governments ban malaria drug for COVID-19,
trial paused as safety fears grow.
May 26, 2020 - Novavax begins human trials for COVID-19 vaccine in Australia
May 26, 2020 - Merck Chairman and CEO
May 21, 2020 - Dr.Paul Stoffels, Johnson & Johnson
Vice Chairman, Status of J&J's Vaccine
May 20, 2020 - New research shows that diabetes medications could treat COVID-19 in diabetes patients
May 15, 2020 - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
Hdroxychloroquine - An old (since the 1930's) anti-malarial drug is now in clinical trials all over the world and has shown to be effective in eliminating the COVID-19 virus from the body. BUT only time will tell if this drug will be a true effective solution until a vaccine can be fully developed.
That said, Teva says it will donate 6 million doses of hydroxychloroquine sulfate tablets
tablets through wholesalers to hospitals by March 31. We expect them to be widely
available in mid-April.
May 14, 2020 Update - NIH begins clinical trial of hydroxychloroquine and azithromycin
to treat COVID-19
* * The projected time for a fully tested vaccine is Spring of 2021. * *
Remdesivir has been studied for years as an experimental antiviral, most recently for its potential against Ebola. Doctors were throwing it against COVID-19 in a "try something" approach, to the point that demand led its manufacturer, Gilead (GILD), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in mid-April, and two more in May.
UPDATE - May 2, 2020 FDA Approves Emergency Use
Convalescent plasma, blood plasma from patients who have recovered from the virus, with their antibodies in it. Still in research, availability at least nine months away. Artificial antibodies, which are similar to blood plasma but more consistent. Trials should begin in early summer, availability possible in the early fall.
April 30, 2020 University of Oxford - Vaccine 'could be ready by end of year'
May 18, 2020 Early data show Moderna Covid-19 vaccine generates immune